2017
DOI: 10.1253/circj.cj-17-0499
|View full text |Cite
|
Sign up to set email alerts
|

Atrial Natriuretic Peptide ― Old But New Therapeutic in Cardiovascular Diseases ―

Abstract: With the discovery of atrial natriuretic peptide (ANP), the heart as an endocrine organ was established. Basic science revealed that ANP, through the particulate guanylyl cyclase A receptor and cGMP, plays a fundamental role in cardiorenal biology. This work has led to the development of ANP as a therapeutic, especially in heart failure (HF). Human genomics has strengthened our understanding of ANP, revealing specific ANP gene variants that may be associated with biological dysfunction, but also may mediate pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0

Year Published

2017
2017
2025
2025

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 27 publications
(15 citation statements)
references
References 70 publications
0
15
0
Order By: Relevance
“…The administration of ANP, BNP, or CNP may also limit post-infarction ventricular remodeling. In decompensated heart failure, ANP and BNP infusion reduces both pulmonary capillary wedge pressure and systemic vascular resistance, thus enhancing stroke volume [for review: ( 51 , 52 )].…”
Section: The Heart As An Endocrine Glandmentioning
confidence: 99%
“…The administration of ANP, BNP, or CNP may also limit post-infarction ventricular remodeling. In decompensated heart failure, ANP and BNP infusion reduces both pulmonary capillary wedge pressure and systemic vascular resistance, thus enhancing stroke volume [for review: ( 51 , 52 )].…”
Section: The Heart As An Endocrine Glandmentioning
confidence: 99%
“…Strategies aimed to chronically inhibit NP degradation might be a way to sustain appropriate systemic NP levels and thus NP signalling in metabolic tissues. Inhibiting NPRC‐mediated, NEP‐mediated or insulin‐degrading‐enzyme‐mediated NP breakdown could be suitable options in this respect, as recently reviewed . Secondly, NP delivery may be envisioned, a therapeutic option in which adequate delivery is crucial to obtain clinical efficacy .…”
Section: Therapeutic Opportunities For Atrial Natriuretic Peptide In mentioning
confidence: 99%
“…Inhibiting NPRC‐mediated, NEP‐mediated or insulin‐degrading‐enzyme‐mediated NP breakdown could be suitable options in this respect, as recently reviewed . Secondly, NP delivery may be envisioned, a therapeutic option in which adequate delivery is crucial to obtain clinical efficacy . In addition to the use of recombinant ANP (carperitide) and BNP (nesiritide) in acute heart failure treatment , the therapeutic potential of these compounds in metabolic diseases may be tested.…”
Section: Therapeutic Opportunities For Atrial Natriuretic Peptide In mentioning
confidence: 99%
“…GCR-A and GCR-B mediate all the main effects of NUP in target cells. These are, first of all, the weakening of fibrotic and hypertrophic myocardial damage [13], vasodilation, inhibition of proliferation of smooth muscle cells, antithrombotic and anti-atherosclerotic action in the vessels [13][14][15], reduction of renin secretion, inhibition of sodium reabsorption in the kidneys and weakening of the sclerosis of the glomeruli, renin and pericanalicular interstitium [16,17]. Increased N0 production by endothelial cells, vasodilation, and the antiproliferative effect of all three NUPs also involve C-type receptors that are not associated with GC, but mediate their effects through Gi proteins that inhibit adenylate cyclase activity in target cells, followed by activation of phospholipase C [18,19].…”
Section: Aimmentioning
confidence: 99%